Immuneering (IMRX) Cash from Financing Activities (2020 - 2026)
Immuneering's (IMRX) quarterly Cash from Financing Activities came in at $180760.0 in Q1 2026, down 98.69% year-on-year from $13.8 million in Q1 2025, and up 150.56% quarter-over-quarter from -$357523.0 in Q4 2025.
Immuneering (IMRX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Immuneering's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $180760.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 98.69% year-over-year to $180760.0 in Q1 2026; TTM through Mar 2026 was $213.0 million, a 1074.32% increase from a year earlier, with the FY2025 full-year figure at $226.6 million, up 4172.32% from the prior year.
- Cash from Financing Activities climbed to $180760.0 in Q1 2026 per IMRX's latest filing, from -$357523.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $213.2 million in Q3 2025 and bottomed at -$357523.0 in Q4 2025.
- The 5-year median for Cash from Financing Activities is $104272.0 (2022), against an average of $16.3 million.
- Across the five-year window, Cash from Financing Activities plunged 2556.14% in 2022 and jumped 101297.86% in 2023, its largest moves.
- Year by year, Cash from Financing Activities stood at -$184677.0 in 2022, then jumped by 104.24% to $7835.0 in 2023, then tumbled by 623.14% to -$40988.0 in 2024, then slumped by 772.26% to -$357523.0 in 2025, then jumped by 150.56% to $180760.0 in 2026.
- Per Business Quant, the three latest IMRX Cash from Financing Activities figures stand at $180760.0 (Q1 2026), -$357523.0 (Q4 2025), and $213.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | 180,760.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180,760.00 |
| Mar 31, 2026 | 180,760.00 |
| Dec 31, 2025 | -357,523.00 |
| Dec 31, 2025 | -357,523.00 |
| Sep 30, 2025 | 213.19 Mn |
| Sep 30, 2025 | 213.19 Mn |
| Jun 30, 2025 | -61,958.00 |
| Jun 30, 2025 | -61,958.00 |
| Mar 31, 2025 | 13.81 Mn |
| Mar 31, 2025 | 13.81 Mn |
| Dec 31, 2024 | -40,988.00 |
| Dec 31, 2024 | -40,988.00 |
| Sep 30, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 979,923.00 |
| Mar 31, 2024 | 979,923.00 |
| Dec 31, 2023 | 7,835.00 |
| Dec 31, 2023 | 7,835.00 |
| Sep 30, 2023 | 21,448.00 |
| Sep 30, 2023 | 21,448.00 |